Dr. Lal PathLabs Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Dr. Lal PathLabs Ltd filed with BSE on 30 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Dr Lal PathLabs reported Q1 FY27 revenue of Rs. 798 crore, up 19.1% year-on-year, driven by patient volume growth of 8.2% and sample volume growth of 10.7%. EBITDA rose 28.7% to Rs. 247 crore with a margin of 31.0%, while profit after tax grew 27.2% to Rs. 170 crore. Management attributed part of the realization growth to CGHS/ECHS price increases and discussed rural outreach expansion, international ventures in Dubai and Ghana, and continued investment in scientific and digital initiatives.
Numbers mentioned
Revenue: Rs. 798 crore (Q1 FY27)
p. 4
“We achieved a revenue of Rs. 798 crore in Q1 FY27, registering a year-on-year growth of 19.1%.”
Shankha Banerjee, page 4 of the filed PDF · View the filing
Patient volume: 8.2 million, growth of 8.2% (Q1 FY27)
p. 4
“The revenue growth is mainly driven by Patient volumes which stood at 8.2 million with a growth of 8.2% and sample volumes which stood at 25.9 million with a growth of 10.7%.”
Shankha Banerjee, page 4 of the filed PDF · View the filing
Revenue per patient: Rs. 968, up 10% (Q1 FY27)
p. 5
“Revenue per patient rose to Rs. 968, up 10% from Rs. 880 in Q1 last year, driven by a favourable change in the test and geography mix and increase in CGHS, ECHS prices.”
Ved Prakash Goel, page 5 of the filed PDF · View the filing
EBITDA: Rs. 247 crore, margin 31.0% (Q1 FY27)
p. 5
“EBITDA for the quarter came in at Rs. 247 crore, v/s Rs. 192 crore in Q1 FY26, with a growth of 28.7%, with EBITDA margin of 31.0%.”
Ved Prakash Goel, page 5 of the filed PDF · View the filing
Profit before tax: Rs. 229 crore, margin 28.7% (Q1 FY27)
p. 5
“Profit before tax rose to Rs. 229 crore from Rs. 181 crore, up 26.3%, with a PBT margin of 28.7%.”
Ved Prakash Goel, page 5 of the filed PDF · View the filing
Profit after tax: Rs. 170 crore, margin 21.4% (Q1 FY27)
p. 6
“Profit after tax stood at Rs. 170 crore, compared to Rs. 134 crore in Q1 FY26, delivering 27.2% growth with a PAT margin of 21.4%.”
Ved Prakash Goel, page 6 of the filed PDF · View the filing
Earnings per share: Rs. 10.1, up 27.8% (Q1 FY27)
p. 6
“Earnings per share for Q1 FY27 came in at Rs. 10.1, up 27.8% from Rs. 7.9 in the corresponding quarter last year.”
Ved Prakash Goel, page 6 of the filed PDF · View the filing
Net cash and equivalents: Rs. 1,693 crore (as of June 30, 2026)
p. 6
“Our balance sheet continues to be strong and resilient, with net cash and equivalents of Rs. 1,693 crore as of June 30, 2026.”
Ved Prakash Goel, page 6 of the filed PDF · View the filing
Test per patient: 3.14 (Q1 FY27)
p. 5
“Test per patient increased to 3.14, compared to 3.07 in the same period last year, highlighting continued traction in our Swasthfit portfolio.”
Ved Prakash Goel, page 5 of the filed PDF · View the filing
Rural outreach patients tested: more than 1,10,000 (Q1 FY27)
p. 3
“we have tested more than 1,10,000 patients in these areas in the first quarter of this year”
Dr. Arvind Lal, page 3 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — mid-teens · FY27
stated conditionally by Shankha Banerjee
p. 8
“chances are we might be more towards mid-teens rather than early teens.”
Shankha Banerjee, page 8 of the filed PDF · View the filing
Patient volume growth — 6%-7% · FY27
stated conditionally by Shankha Banerjee
p. 7
“At the beginning of the year, I think we had said that we are looking at a volume growth, which is patient volume, between 6%-7%.”
Shankha Banerjee, page 7 of the filed PDF · View the filing
CGHS/ECHS price benefit — 2%-3% at company level · next 2-3 quarters
stated firmly by Shankha Banerjee
p. 6
“Our assessment is that it kind of is to the tune of between 2%-3% at an overall company level. And I think this benefit will continue for at least another 2-3 quarters.”
Shankha Banerjee, page 6 of the filed PDF · View the filing
Lab additions — 12-15 labs · FY27
stated firmly by Shankha Banerjee
p. 10
“We are looking at between 12-15 labs to be added this year as well.”
Shankha Banerjee, page 10 of the filed PDF · View the filing
Radiology center additions outside Delhi NCR — three to four centers · this year
stated as an aspiration by Shankha Banerjee
p. 10
“It could be maybe three to four centers this year.”
Shankha Banerjee, page 10 of the filed PDF · View the filing
Capex — Rs. 140 crore to Rs. 150 crore · this year and next year
stated firmly by Ved Prakash Goel
p. 21
“We touch roughly about Rs. 140 crore to Rs. 150 crore.”
Ved Prakash Goel, page 21 of the filed PDF · View the filing
EBITDA margin guidance — 27%-28% · FY27
stated conditionally by Ved Prakash Goel
p. 17
“we will be in a better position after maybe Q2 whether it is panning out or we will change our guidance on that.”
Ved Prakash Goel, page 17 of the filed PDF · View the filing
Price increase decision — second half of the year
stated conditionally by Shankha Banerjee
p. 7
“we would be thinking about something related to price only towards the end of the year”
Shankha Banerjee, page 7 of the filed PDF · View the filing
International business contribution — 3-5 year horizon
stated as an aspiration by Shankha Banerjee
p. 10
“the idea is yes, over a slightly longer-term horizon, we should be able to increase the contribution from international.”
Shankha Banerjee, page 10 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
CGHS/ECHS contributed 2-3% at company level, benefit expected to continue 2-3 quarters.
Answered by Shankha Banerjee
Asked by Amey Chalke: How much of revenue per patient growth came from CGHS price hikes, and will growth accelerate for the year?
p. 6
“Our assessment is that it kind of is to the tune of between 2%-3% at an overall company level.”
Shankha Banerjee, page 6 of the filed PDF · View the filing
Management indicated results may trend towards mid-teens rather than early teens after a strong Q1.
Answered by Shankha Banerjee
Asked by Tausif Shaikh: Does the company maintain guidance of mid-teens revenue growth and 27-28% EBITDA margin?
p. 8
“chances are we might be more towards mid-teens rather than early teens.”
Shankha Banerjee, page 8 of the filed PDF · View the filing
Management expects the growth to be sustained given wider adoption in Tier 2/3 markets.
Answered by Shankha Banerjee
Asked by Yogesh Soni: Will Swasthfit sustain its high-teens to 20% growth?
p. 8
“we believe that this growth rate we should be able to sustain for some more time.”
Shankha Banerjee, page 8 of the filed PDF · View the filing
Similar to last year, with 12-15 new labs planned.
Answered by Shankha Banerjee
Asked by Anshul Agrawal: What is the plan for lab additions this year?
p. 10
“Yes, it is going to be more like last year. We are looking at between 12-15 labs to be added this year as well.”
Shankha Banerjee, page 10 of the filed PDF · View the filing
Suburban's growth is improving and nearing double digits after integration issues.
Answered by Shankha Banerjee
Asked by Prakash Kapadia: How is the West India (Suburban) business performing post-integration?
p. 11
“it is very close double digits actually right now in terms of growth.”
Shankha Banerjee, page 11 of the filed PDF · View the filing
New tests are developed both in-house and via partnerships, aimed at deepening clinician relationships rather than standalone revenue.
Answered by Shankha Banerjee
Asked by Saion Mukherjee: What is the market opportunity for new tests and are they developed in-house or via partnerships?
p. 12
“I think there are both kinds, but right now a lot of this is in partnership, including international partnerships.”
Shankha Banerjee, page 12 of the filed PDF · View the filing
Higher realization specialized test portfolio outside Swasthfit is also growing well.
Answered by Shankha Banerjee
Asked by Shyam Srinivasan: What explains the increase in revenue per patient beyond CGHS and Swasthfit contribution?
p. 13
“we have a specialized test portfolio which has higher realizations and even that portfolio has done well.”
Shankha Banerjee, page 13 of the filed PDF · View the filing
Management said growth is broad-based across geographies but it's too early to identify a specific structural trigger.
Answered by Shankha Banerjee
Asked by Rahul Jeewani: Is there a structural change driving industry-wide growth acceleration beyond CGHS increases?
p. 14
“there is no other differential trigger that we have been able to identify as of now. But the growth is from all around.”
Shankha Banerjee, page 14 of the filed PDF · View the filing
Management said they would primarily reinvest and clarify guidance after Q2.
Answered by Shankha Banerjee
Asked by Sudharshan: Will CGHS-driven margin benefit lead to an upgrade in margin guidance or be reinvested?
p. 14
“the idea always is to reinvest for future growth. That is the dominant idea.”
Shankha Banerjee, page 14 of the filed PDF · View the filing
No major impact currently, though currency and inflation could affect imported material costs if issues persist.
Answered by Ved Prakash Goel
Asked by Abdul Puranwala: Is there cost escalation risk from geopolitical issues affecting material costs?
p. 16
“if this continues then obviously movement in currency and overall inflation may impact our material cost because we use most of the imported material for testing.”
Ved Prakash Goel, page 16 of the filed PDF · View the filing
B2C contribution remains around 75%, a mix management is comfortable maintaining.
Answered by Shankha Banerjee
Asked by Sumit Gupta: What is the B2C/B2B mix and is it expected to change?
p. 17
“B2C contribution for us has been in the range of 75% and even this quarter it is in a similar ratio.”
Shankha Banerjee, page 17 of the filed PDF · View the filing
Tier 3 and below markets contributed about 39% of revenue in the last financial year.
Answered by Shankha Banerjee
Asked by Surya Narayan Patra: What proportion of network/revenue comes from Tier 3 and below markets?
p. 19
“Tier 3 and below has is about 39% of our revenue in the last financial year.”
Shankha Banerjee, page 19 of the filed PDF · View the filing
Cash will primarily be used for M&A, especially in underrepresented western and southern markets, and radiology center capex.
Answered by Shankha Banerjee
Asked by Mohammed Patel: How will the company utilize its cash reserves and what is the capital allocation plan?
p. 20
“one of the major utilization of cash as we see going forward would be for M&As.”
Shankha Banerjee, page 20 of the filed PDF · View the filing
Risks flagged
Uncertain weather pattern this quarter and its unclear impact on diagnostic testing demand
p. 16
“quarter 1 definitely has seen a very different kind of a weather pattern than maybe what we are normally used to in quarter 1.”
Shankha Banerjee, page 16 of the filed PDF · View the filing
Potential impact of currency movement and inflation on imported material costs
p. 16
“movement in currency and overall inflation may impact our material cost because we use most of the imported material for testing”
Ved Prakash Goel, page 16 of the filed PDF · View the filing
Persistently intense competition in the diagnostics industry
p. 18
“competition in the industry has always been intense and is likely to stay intense.”
Shankha Banerjee, page 18 of the filed PDF · View the filing
Low entry barriers allowing smaller labs to continue entering the market
p. 18
“there are still low entry barriers and therefore, at the bottom end there could still be smaller labs entering the fray.”
Shankha Banerjee, page 18 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.